Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 5, 2019- As reported, full fiscal year revenues of $17.290 billion increased 8.2 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.584 billion for the fourth fiscal quarter ended September 30,...
-
Oct 29, 2019
FRANKLIN LAKES, N.J., and WAGENINGEN, THE NETHERLANDS, October 29, 2019 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points...
-
Oct 28, 2019BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit is designed and tested to work with BD Rhapsody™ Single-Cell Analysis System, BD® AbSeq reagents and BD® Single-Cell Multiplexing Kit
Franklin Lakes, N.J., October 28, 2019 – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the availability of BD Rhapsody WTA Amplification kit...
-
Oct 3, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2019 earnings conference call on Tuesday,...
-
Sep 28, 2019Independent analysis of LUTONIX® 035 Drug Coated Balloon patient-level data showed no statistically significant mortality increase
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a company-initiated, independent analysis of the LUTONIX® 035 Drug...
Sep 26, 2019Thomas E. Polen Appointed Chief Executive Officer, Effective Jan. 28, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vincent A. Forlenza, chairman and CEO, will retire as CEO on Jan. 28, 2020,...
Aug 21, 2019BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor healthcare conferences: Wells...
Aug 6, 2019- As reported, revenues of $4.350 billion increased 1.7 percent.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.350 billion for the third fiscal quarter ended June 30, 2019....
-
Jul 23, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2018 Sustainability Report, focusing on management of the environmental, social and...
-
Jul 22, 2019
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 per common share, payable on September 30, 2019 to holders of record on...